INTINI, ROSSANA

INTINI, ROSSANA  

Mostra records
Risultati 1 - 9 di 9 (tempo di esecuzione: 0.021 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
Immunotherapy in Gastrointestinal Cancers 2017 Procaccio, LetiziaFassan, MatteoPrete, Alessandra AnnaIntini, RossanaBoscolo, AliceZagonel, VittorinaLonardi, Sara + BIOMED RESEARCH INTERNATIONAL - -
Immunotherapy in Gastrointestinal Cancers 2017 Procaccio, LetiziaFassan, MatteoBergamo, FrancescaPrete, Alessandra AnnaIntini, RossanaBoscolo, AliceZagonel, VittorinaLonardi, Sara + BIOMED RESEARCH INTERNATIONAL - -
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer? 2018 Loupakis, FotiosINTINI, ROSSANABergamo, FrancescaBertorelle, RobertaFassan, MatteoMerigliano, StefanoPilati, PierluigiUrso, Emanuele Luca DamianoCillo, UmbertoRugge, MassimoLonardi, SaraZagonel, Vittorina + THE ONCOLOGIST - -
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 2019 Loupakis F.Intini R.Buggin, FedericaPRETE, ALESSANDRA ANNALonardi S.Zagonel V.Fassan M. + EUROPEAN JOURNAL OF CANCER - -
CK7 and consensus molecular subtypes as major prognosticators in V600E BRAF mutated metastatic colorectal cancer 2019 Loupakis F.Prete A. A.Intini R.Guzzardo V.Mescoli C.Lonardi S.Rugge M.Zagonel V.Fassan M. + BRITISH JOURNAL OF CANCER - -
Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes 2020 Loupakis F.Intini R.Prete A. A.Lombardi P.Spallanzani A.Maddalena G.Salmaso R.Munari G.Rugge M.Dei Tos A. P.Schirripa M.Zagonel V.Lonardi S.Fassan M. + THE ONCOLOGIST - -
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 2021 Lonardi S.Intini R.Salati M.Belli C.Brambilla M.Prete A. A.Fassan M.Ambrosini M.Zagonel V. + EUROPEAN JOURNAL OF CANCER - -
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? 2022 Moretto R.Rossini D.Intini R.Rasola C.Salati M.Fassan M.Lonardi S. + BRITISH JOURNAL OF CANCER - -
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer 2022 Intini R.Angerilli V.Fassan M.Lonardi S. + EUROPEAN JOURNAL OF CANCER - -